Appropriate therapeutic measures are taken based on different breast cancer subtypes, such as HR+/ERBB2− (seven-tenths of the total), ERBB2+ (one-fifth of the total) as well as triple-negative (one-tenth of the total). The gene discussed is ERBB2; the disease is breast carcinoma.